MicroRNA-29c targets β-site amyloid precursor protein-cleaving enzyme 1 and has a neuroprotective role in vitro and in vivo

Molecular Medicine Reports

Volumn 12, Issue 2, 2015, Pages 3081-3088

  Yang, Guoshuai ^a,b   Song, Yanmin ^c   Zhou, Xiaoyan ^b   Deng, Yidong ^a   Liu, Tao ^a   Weng, Guohu ^a   Yu, Dan ^b   Pan, Suyue ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b HAIKOU PEOPLE S HOSPITAL   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Memory; MicroRNA; Protein kinase A; site amyloid precursor protein cleaving enzyme 1

Indexed keywords

BETA ACTIN; BETA SECRETASE 1; CYCLIC AMP DEPENDENT PROTEIN KINASE; MESSENGER RNA; MICRORNA; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; CREBBP PROTEIN, MOUSE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; MIRN29 MICRORNA, HUMAN; SECRETASE;

3' UNTRANSLATED REGION; AGED; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BRAIN NERVE CELL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE TARGETING; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY; MOUSE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CASE CONTROL STUDY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; MAZE TEST; METABOLISM; NERVE CELL; PATHOLOGY; PRIMARY CELL CULTURE; TRANSGENIC MOUSE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CASE-CONTROL STUDIES; CELL PROLIFERATION; CREB-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; MALE; MAZE LEARNING; MICE; MICE, TRANSGENIC; MICRORNAS; NEURONS; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION;

EID: 84988667424     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3728     Document Type: Article

References (27)

1. Maciotta S, Meregalli M and Torrente Y: The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci 7: 265, 2013.
2. Rao AT, Degnan AJ and Levy LM: Genetics of Alzheimer disease. AJNR Am J Neuroradiol 35: 457-458, 2014
3. Davinelli S, Calabrese V, Zella D and Scapagnini G: Epigenetic nutraceutical diets in Alzheimer's disease. J Nutr Health Aging 18: 800-805, 2014
4. Wirth M, Villeneuve S, La Joie R, Marks SM and Jagust WJ: Gene-environment interactions: Lifetime cognitive activity, APOE genotype, and β-amyloid burden. J Neurosci 34: 8612-8617, 2014
5. Hébert SS, Horré K, Nicolaï L, et al: Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc Natl Acad Sci USA 105: 6415-6420, 2008.
6. Selbach M, Schwanhäusser B, Thierfelder N, et al: Widespread changes in protein synthesis induced by microRNAs. Nature 455:58-63, 2008.
7. Fineberg SK, Kosik KS and Davidson BL: MicroRNAs potentiate neural development. Neuron 64: 303-309, 2009.
8. Hampel H, Shen Y, Walsh DM, et al: Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Exp Neurol 223: 334-346, 2010.
9. Wang WX, Rajeev BW, Stromberg AJ, et al: The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28: 1213-1223, 2008.
10. Kocerha J, Kauppinen S and Wahlestedt C: microRNAs in CNS disorders. Neuromolecular Med 11: 162-172, 2009
11. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th edition, National Academies Press, Washington DC, US, 2011.
12. Livak KF and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.
13. Decourt B, Walker A, Gonzales A, et al: Can platelet BACE1 levels be used as a biomarker for Alzheimer's disease? Proof-of-concept study. Platelets 24: 235-238, 2013.
14. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al: Alzheimer's Disease Neuroimaging Initiative: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65: 403-413, 2009
15. Bibl M, Esselmann H, Lewczuk P, et al: Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. Int J Alzheimers Dis pii: 761571, 2010
16. Müller M, Kuiperij HB, Claassen JA, Küsters B and Verbeek MM: MicroRNAs in Alzheimer's disease: Differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging 35: 152-158, 2014
17. Bettens K, Brouwers N, Engelborghs S, et al: APP and BACE1 miRNA genetic variability has no major role in risk for Alzheimer disease. Hum Mutat 30: 1207-1213, 2009
18. Marques SC, Lemos R, Ferreiro E, et al: Epigenetic regulation of BACE1 in Alzheimer's disease patients and in transgenic mice. Neuroscience 220: 256-266, 2012.
19. Cattabeni F, Colciaghi F and Di Luca M: Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry 28: 763-770, 2004
20. Zong Y, Wang H, Dong W, et al: miR-29c regulates BACE1 protein expression. Brain Res 1395: 108-115, 2011.
21. Cogswell JP, Ward J, Taylor IA, et al: Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14: 27-41, 2008.
22. Moon M, Cha MY and Mook-Jung I: Impaired hippocampal neurogenesis and its enhancement with ghrelin in 5XFAD mice. J Alzheimers Dis 41: 233-241, 2014
23. Shi YQ, Huang TW, Chen LM, et al: Ginsenoside Rg1 attenuates amyloid-beta content, regulates PKA/CREB activity and improves cognitive performance in SAMP8 mice. J Alzheimers Dis 19: 977-989, 2010.
24. Valera E, Sánchez-Martín FJ, Ferrer-Montiel AV, Messeguer A and Merino JM: NMDA-induced neuroprotection in hippocampal neurons is mediated through the protein kinase A and CREB (cAMP-response element-binding protein) pathway. Neurochem Int 53: 148-154, 2008.
25. Zeitlin R, Patel S, Burgess S, Arendash GW and Echeverria V: Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. Brain Res 1417: 127-136, 2011.
26. Sierksma AS, Rutten K, Sydlik S, et al: Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease. Neuropharmacology 64: 124-136, 2013.
27. Chen Y, Huang X, Zhang YW, et al: Alzheimer's β-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of β-amyloid. J Neurosci 32: 11390-11395, 2012.